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As platelets are rich in growth factors for tissue regeneration, autologous platelet-rich plasma (PRP) has
been used to treat some refractory corneal defects. Although PRP is effective, the cost of its preparation is
very high. This article presents three cases of refractory corneal ulcer under the prescription of autolo-
gous PRP. The autologous PRP used in these cases was easily prepared in the blood bank laboratory. In
this paper, we collected three patients with refractory corneal ulcer who were unresponsive to con-
ventional treatment. The patients presented with neurotrophic ulcer, exposure corneal ulcer, and limbal
deciency with corneal ulcer after hepatitic keratitis. Although we easily prepared autologous PRP eye
drops using simple laboratory centrifugation, this preparation still had a clinical effect on corneal defect.
The mean intervention time was 24 ± 6.9 days. The case with exposure corneal ulcer had signiﬁcant
wound healing and the other two cases felt subjective symptom relief. There were some clinical im-
provements of refractory corneal ulcers in our three cases. We present the clinical results of three cases
and report an easy procedure for the preparation of autologous PRP. Autologous PRP prepared simply in
the laboratory, it may be an alternative option for treating refractory corneal ulcer.
Copyright © 2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
The treatment of refractive corneal ulcer still poses a challenge
to many ophthalmologists. Previous therapeutic modalities include
the use of bandage contact lenses, topical artiﬁcial tears, sodium
hyaluronate, and autologous serum with ﬁbronectin, substance P,
or insulin-like growth factor 1.1 Topical application of serum eye
drops has been reported to accelerate healing of persistent ocular
surface defects.
Autologous platelet-rich plasma (PRP) has also been proven to
beneﬁcial in cell proliferation and wound healing.2 The difference
between autologous PRP and autologous serum is the platelets
preserved in the autologous PRP. Platelets are great sources ofnterests to disclose.
ology, Shin Kong Wu Ho-Su
ih-Lin District, Taipei 11120,
).
ciety of Taiwan. Published by Elsegrowth factors such as platelet-derived growth factors (PDGFs) aa,
bb, and ab, transforming growth factors (TGFs) b1 and b2, vascular
endothelial growth factor, and epithelial growth factor. Platelets
also adhere to the damaged vascular endothelium and start a
healing reaction that includes the release of numerous cytokines
and growth factors.3 Autologous PRP is rich in growth factors
known for healing epithelial and internal wounds. Clinically, some
ocular surface defects such as dormant corneal ulcer, dry eye, and
ocular surface syndrome have been treatedwith autologous PRP.2e7
As a complement to tissue regeneration procedures, PRP also sup-
ports the wound healing process in other specialties such as oral
and maxillofacial surgery, reconstructive surgery, orthopedics,
cardiovascular surgery, and plastic surgery.8e15
The conventional production of autologous PRP is complicated,
involving large volumes of whole blood (500 mL), and a hospital
environment with sophisticated and expensive equipment. This
article presents three cases of refractory corneal ulcer under the
prescription of autologous PRP that was easily prepared in the
laboratory.vier Taiwan LLC. All rights reserved.
Table 1
Platelet count in whole blood and platelet-rich plasma (PRP).
Platelet count in whole blood Platelet count in PRP
Case A 134.67 ± 6.11  109/L 377.67 ± 76.79  109/L
Case B 215.67 ± 5.86  109/L 580.653 ± 52.56  109/L
Case C 366 ± 42.22  109/L 795.33 ± 16.04  109/L
All patient data including prothrombin time and activated partial thromboplastin
time tests were normal.
T.E. Wu et al. / Taiwan Journal of Ophthalmology 5 (2015) 132e135 1332. Study design and methods
2.1. Participants
Four eyes of three patients with refractory corneal ulcers were
treated at the Department of Ophthalmology Shin-Kong Wu Ho-Su
Memorial Hospital in Taipei, Taiwan. This research was conducted
with the approval of the Institutional Review Board.
2.2. Patients and examinations
In this study, we included three patients with refractory corneal
ulcer. The mean age of the patients was 45.67 ± 30.17 years (range,
11e66 years). Their respective histories are brieﬂy described as
follows.
Case Awas a 66-year-old womanwho had underlying history of
uremia on hemodialysis, diabetes mellitus, and hypertension for
many years. She initially presented with bilateral refractory neu-
rotrophic corneal ulcers: 9.3 mm  5.2 mm diffuse corneal ulcer in
the right eye and a 7.7 mm 3.2 mm band form corneal ulcer in the
left. Vision was only counting ﬁngers at 30 cm in both eyes. The
patient suffered from persistent ocular irritation and mucus
discharge for about 1month. Bacterial culture of the cornea showed
no growth. We had already used nonpreserved artiﬁcial tears and
antibiotic eye drops to protect the cornea. We also used therapeutic
contact lenses for the neurotrophic ulcers. However, the corneal
wound was persistent, so we added autologous PRP every 2 hours
except sleep for 17 days.
Case B was a 60-year-old woman who had cataract surgery
previously. Several months earlier she had received surgery for
skull base meningioma, but she complained of an impairment in
closing the right eye. The neurosurgeon prescribed lubrication for
her. She visited our ophthalmology department because of vision
change, severe eye congestion, and pain for 2 weeks. Her vision in
the right eye was changed from 6/10 to 6/60. The right eye pre-
sented a diffuse corneal epithelial defect with severe inﬁltration
almost in whole cornea. She refused tarsorraphy for exposure
corneal ulcer. We used autologous PRP every 2 hours and topical
antibiotic medication for 21 days.
Case C was a 9-year-old girl who had history of right eye
amblyopia. She also had suffered from persistent herpetic keratitis
4 years earlier on the same-side right eye. After the infection, the
right eye developed macular cornea, corneal scar, and neo-
vascularization. Vision was only light perception in the right eye.
Because of limbal deﬁciency, she suffered from recurrent ocular
irritation, corneal ulcer, and stromal inﬁltration. Although we
have used many lubricants to the irregular ocular surface, she still
often complained of burning pain and discharge. Trying to relieve
the symptom, she received autologous PRP every 2 hours for 35
days.
All the three patients were refractory to conventional treatment
for corneal ulcer, such as preservative-free artiﬁcial tears, sodium
hyaluronate eye drops, patching, or soft therapeutic contact lens
applications.
2.3. Preparation of autologous PRP
In our blood bank, 20 mL of whole blood from each patient was
taken by venipuncture. Before venipuncture, we used Sindine so-
lution (povidone iodine 10% 200 mL/BT) and alcohol swab (iso-
propyl alcohol 70%) to scrub the area at least 4 cm in all directions
from the intended site of venipuncture three times. Blood samples
were drawn into 20-mL syringes. Then we transferred 2 mL into a
tube (K2-EDTA) for complete blood count (Sysmex XE5000), and
18 mL blood into sterile glass tube with 2 mL of anticoagulantCPDA-1 in preparation for autologous PRP. Samples were gently
agitated to mix the anticoagulant thoroughly with the whole blood
and centrifuged for 10minutes at 800 rpm (KA1000A Kubota). After
centrifugation, the upper fraction of each sample was 2e3 mL PRP.
Plasma was separated carefully in a sterile manner under clean
bench conditions. Then 1.0 mL plasmawas counted for platelet data
with Sysmex XE5000 (Sysmex Corporation, Europe GmbH, Born-
barch 1, 22848 Norderstedt, Germany), and the remaining
1.0e2.0 mL plasma was collected as the ﬁnal autologous PRP
product. To minimize contamination, we discarded all 5 mL of
antibiotic eye drops from its sterile bottle and used this emptied
bottle for storage of autologous PRP.
Patients were instructed to keep their current bottles in a dark,
cool place under refrigeration at þ4C. Every week, we prepared a
new bottle for each patient to keep autologous PRP fresh and avoid
patient infection.
Autologous PRP was administered to patients once every
2 hours daily as required in addition to preservative-free artiﬁcial
tears for at least 1 week. All topical medications were discontinued
with the resolution of the corneal lesions or limited response after
35 days.
3. Results
3.1. Laboratory test of autologous PRP
The results of laboratory tests are shown in Table 1. The result of
microbiology tests were: the autologous PRP of Cases B and C was
normal, but autologous PRP eye drops of Case A on second exam-
ination were found to contain Stenotrophomonas maltophilia.
3.2. Clinical features
Refractory corneal ulcer of diabetic Case A had chronic stromal
inﬁltration and corneal scarring for a long time. The neurotrophic
ulcer showed limited response to autologous PRP. Clinically, the
epithelial defect still persisted and stromal inﬁltration had little
improvement after 17 days treatment with autologous PRP. How-
ever, the patient mentioned that foreign body sensation improved
subjectively. The mucus discharge and ocular congestion were
decreased after autologous PRP treatment (Fig. 1).
The diffuse epithelial defect in Case B was almost healed after 21
days of PRP treatment (Fig. 2). The patient reported a gradual
decrease of ocular discomfort and felt that vision improved week-
by-week. Her vision recovered to 6/10. The exposure keratopathy
subsided without the need for a more aggressive surgical
procedure.
The refractory corneal ulcer of Case B with stromal inﬁltration
induced by herpetic keratitis shows mild improvement (Fig. 3).
The subjective symptoms such as burning pain and dischargewere
relieved. Meanwhile, the corneal neovascularization and
conjunctival congestion declined moderately. The girl was happy
to return to her daily activities because of ocular symptom
improvement.
Fig. 1. Case A. Diabetic corneal erosions in both eyes (A: right eye; B: left eye) before treatment by topical autologous platelet-rich plasma. Note the diffuse corneal defect and
haziness. The corneal epithelial defect healed subclinically after 17 days, with a notable decrease in foreign body sensation (C: right eye; D: left eye).
Fig. 2. Case B. (A) Exposure keratopathy under ﬂuorescence stain before treatment. (B) The corneal epithelial defect almost healed with a notable decrease in corneal haziness
within 21 days.
Fig. 3. Case C. (A) Persistent herpetic keratitis before treatment. Note the stromal inﬁltration (arrowhead) and neovascularization (white arrow). (B) The corneal epithelial defect
and stromal inﬁltration moderately decreased after 35 days of platelet-rich plasma treatment.
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keratopathy (Case B) improved signiﬁcantly after 21 days of
application of autologous PRP. However, in diabetic Case A, re-
fractory corneal ulcer with corneal scarring and stromal inﬁltra-
tion showed the least response to autologous PRP in this case
series.4. Discussion
Autologous PRP has been proven to be very effective for tissue
regeneration and wound healing.2e7,16e18 Because PRP is developed
from autologous blood, it is inherently safe and free from trans-
missible diseases such as HIV and hepatitis. With PRP, the increased
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to the surgical area. The seven known growth factors in PRP are:
PDGFs aa, bb, and ab, TGF-b1 and -b2, vascular endothelial growth
factor, and epithelial growth factor. These are native growth factors
in their biologically determined ratios.16e19 As with other tissues,
wound healing in the cornea is controlled by a variety of growth
factors and other substances inﬂuencing proliferation, differentia-
tion, and migration of corneal epithelial cells, which in parts reach
the ocular surface via the natural tear ﬁlm. Epithelial growth factor
supports proliferation andmigration of epithelial cells and seems to
inhibit apoptosis. PDGF, hepatocyte growth factor, and ﬁbroblast
growth factor are stimuli of cell proliferation, whereas TGF-b seems
to inhibit corneal epithelial cell proliferation and enhances
apoptosis.14,15 Generally, these biologic products of PRP are manu-
factured through a particular kit under good manufacturing prac-
tice conditions. When manufacturing a biologic PRP, it is essential
to have established speciﬁcations to assure safety, purity, and po-
tency. The cost expansion of manufacturing PRP is very high, so PRP
possibly could be used only in some higher economic populations.
As far as we know, this is the ﬁrst report to present a process
that was not through a particular kit and manufacture cabinet, but
provided a preparation regimen of autologous PRP in the labora-
tory. We analyzed our easy-to-prepare autologous PRP, which
resulted in a two- to three-fold enrichment of platelet. The quality
was good enough to approach the treatment level. Costs seem to
be lower without requiring speciﬁc equipment and high-cost
disposable kit.18 For topical ocular surface defects, easily preparing
growth factors of PRP in a blood bank laboratory is attractive.
However, there are concerns about safety and traceability because
of the risk of bacterial contamination. To avoid the risk of infection,
we put PRP in an empty bottle of antibiotic eye drops and stored it
in the refrigerator at 4C.19 At each weekly visit, we also monitored
the condition of PRP including the platelet count and bacterial
culture. In all 11 PRP preparations from three patients, only one
positive bacterial culture was found from the diabetic patient (Case
A). From the second PRP sample of Case A, we cultured Steno-
trophomonas maltophilia; however, blood culture of this patient
revealed no bacteremia. This implies that the bacteria strains may
have been the result of contamination. Although it is possible that
this was a false-positive culture result, there are no data provided
to support this conclusion. Absolutely, we should perform aseptic
procedures more carefully to prevent sample contamination in
laboratory. The patients need more health education for PRP usage
at home.17,18
PRP is deﬁned as a portion of the plasma fraction of autologous
blood having a platelet concentration above baseline.20 PRP has
more concentrated platelets than normal plasma (approximately
150e400  109/L). In such conditions, PRP contains not only a high
level of platelets, but also the full complement of clotting factors,
the latter of which typically remain at their normal physiologic
levels. In blood cell analysis, Lee et al21 reported that the platelet
count of the PRP group was approximately 4.25 times higher than
that of the whole blood group using a manufacturing process.
Although using a centrifuge in our easy-to-prepare method did not
give a platelet count as high as previously reported, this method
still provided platelet preparations that were concentrated two- to
three-fold over total blood values.21 According to the clinical re-
sults, the easy-to-prepare autologous PRP still worked.Although there are only three cases reports here, we found that
autologous PRP has a potential role for treating refractive corneal
ulcer. Compared to diffuse superﬁcial corneal ulcer, PRP has limited
effect on corneal scar or deep stromal inﬁltration. The platelet
concentration of the easily prepared autologous PRP is lower than
those of specialized procedures, but this autologous PRP from our
laboratory could be used in situations where manufacturing a
biologic PRP is not practical.References
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